Sun Pharmaceutical Industries Ltd., India’s largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women’s health and biosimilars. The potential deal, valued at $10 billion, is being led by the company’s founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for Sun Pharma, enabling the company to expand its presence in the lucrative US market and accelerate its growth in the high-potential biosimilars sector.<\/p>\n
The acquisition of Organon would provide Sun Pharma with a substantial boost in the US market, where the company has been seeking to increase its presence. Organon’s portfolio of women’s health products and biosimilars would complement Sun Pharma’s existing product line, enabling the company to offer a more comprehensive range of treatments to patients. Additionally, the deal would grant Sun Pharma access to Organon’s established distribution network and sales infrastructure in the US, facilitating the company’s ability to reach a broader customer base.<\/p>\n
The biosimilars sector is a high-growth area, with increasing demand for affordable alternatives to branded biologic medications. By acquiring Organon, Sun Pharma would gain a significant foothold in this market, enabling the company to capitalize on the growing demand for biosimilars. The deal would also provide Sun Pharma with the opportunity to leverage Organon’s expertise in developing and commercializing biosimilars, further enhancing the company’s capabilities in this area.<\/p>\n
The potential acquisition of Organon is a testament to Sun Pharma’s ambition to become a leading global pharmaceutical player. Under the leadership of Dilip Shanghvi, the company has been actively pursuing strategic acquisitions and partnerships to drive growth and expansion. The acquisition of Organon would be a major milestone in this journey, marking a significant step towards establishing Sun Pharma as a major player in the global pharmaceutical industry.<\/p>\n
Overall, the potential acquisition of Organon by Sun Pharma is a significant development in the pharmaceutical industry, with far-reaching implications for the company’s growth and expansion. If successful, the deal would enable Sun Pharma to establish a strong presence in the US market, accelerate its growth in the biosimilars sector, and cement its position as a leading global pharmaceutical player.<\/p>\n","protected":false},"excerpt":{"rendered":"
Sun Pharmaceutical Industries Ltd., India’s largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women’s health and biosimilars. The potential deal, valued at $10 billion, is being led by the company’s founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for Sun Pharma, enabling the company […]<\/p>\n","protected":false},"author":1,"featured_media":88143,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2,16],"tags":[],"class_list":["post-89821","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma","category-sun-pharma"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89871,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/28\/sun-pharma-receives-green-light-for-obesity-treatment-injection-similar-to-wegovy\/","url_meta":{"origin":89821,"position":0},"title":"Sun Pharma receives green light for obesity treatment injection similar to Wegovy.","author":"Team Small News","date":"January 28, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk's Wegovy. The new treatment, called \"SUN-144\", is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89791,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/aurobindo-pharma-acquires-khandelwal-labs-non-cancer-portfolio-for-%e2%82%b9325-crore\/","url_meta":{"origin":89821,"position":1},"title":"Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for \u20b9325 Crore.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for \u20b9325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market. Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89877,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/29\/sp-global-upgrades-biocon-biologics-credit-rating-to-bb-with-a-stable-outlook-reports-indiamedtoday\/","url_meta":{"origin":89821,"position":2},"title":"S&P Global Upgrades Biocon Biologics’ Credit Rating to ‘BB+’ with a Stable Outlook, Reports IndiaMedToday","author":"Team Small News","date":"January 29, 2026","format":false,"excerpt":"S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to 'BB+' from 'BB'. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament to Biocon Biologics' strong business profile, driven by its robust product\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89749,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/aurobindo-pharma-pushes-back-deadline-to-purchase-26-stake-in-swarnaakshu-solar\/","url_meta":{"origin":89821,"position":3},"title":"Aurobindo Pharma Pushes Back Deadline to Purchase 26% Stake in Swarnaakshu Solar","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma's strategy to diversify its business and invest in renewable energy. The company had initially planned to complete the acquisition by a certain deadline, but it\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89824,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/biocon-expects-robust-q3-performance-fueled-by-biosimilar-growth\/","url_meta":{"origin":89821,"position":4},"title":"Biocon Expects Robust Q3 Performance Fueled by Biosimilar Growth","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Biocon, a leading biopharmaceutical company, is expected to have a strong third quarter in the fiscal year 2026 (Q3FY26). The company's biosimilars segment is anticipated to drive this growth, with key products such as bStelara playing a significant role. Analysts predict substantial revenue growth, driven by the increasing adoption of\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89764,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/biocon-biologics-enhances-its-cancer-treatment-offerings-with-the-introduction-of-three-key-biosimilar-products\/","url_meta":{"origin":89821,"position":5},"title":"Biocon Biologics enhances its cancer treatment offerings with the introduction of three key biosimilar products.","author":"Team Small News","date":"January 7, 2026","format":false,"excerpt":"Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab\/Hyaluronidase, Nivolumab, and Pembrolizumab, which are used to treat various types of cancer. With these new additions, Biocon\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89821"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89821\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88143"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}